

November 7, 1968

Dr. Doris H. Clouet
Associate Research Scientist
New York State Research Institute
Ward's Island, New York 10035

Dear Doris,

Thank you very much for the invitation to participate in your volume "Biochemistry of Addiction". I have discussed the outline with my associates and would like to share some of our comments with you.

The suggestion of a description of the clinical use of narcotic antagonists in a volume dedicated heavily to basic science aspects is commendable, but one that will contribute little to the overall volume. In part, we fear that such a chapter will be lost since the majority of readers will be basic scientists.

In reading the list of titles, it seems to us that a chapter on the neurophysiology of heroin, and our experiments on its antagonism to methadone, cyclazocine and naloxone; and indeed, the experiences and potential usefulness of a heroin challenge test might be a more useful section. Especially, if it were introduced in the volume as part of Section V. Such a chapter could fall in Section IX.

We would propose to participate in this volume by providing a chapter on our neurophysiological studies. I am not sure how such data, especially since it would be heavily weighted with EEG figures, would be interpreted by biochemists reading the volume, but I am optimistic that the next few years may bring forth some theories of the relation of EEG changes to the biochemical changes of the brain. When that occurs, our data may be usefully interpreted by chemists.

If this suggestion is not consistent with your overall picture of the volume, and you still would like a clinical evaluation of the antagonists, we will be able to provide an up-to-date summary in the early spring. As co-contributors, I would like to invite Dr. Arthur Zaks and Dr. Alfred M. Freedman.

November 7, 1968

Dr. Doris H. Clouet
Associate Research Scientist
New York State Research Institute
Ward's Island, New York 10035

Dear Doris,

Thank you very much for the invitation to participate in your volume "Biochemistry of Addiction". I have discussed the outline with my associates and would like to share some of our comments with you.

The suggestion of a description of the clinical use of narcotic antagonists in a volume dedicated heavily to basic science aspects is commendable, but one that will contribute little to the overall volume. In part, we fear that such a chapter will be lost since the majority of readers will be basic scientists.

In reading the list of titles, it seems to us that a chapter on the neurophysiology of heroin, and our experiments on its antagonism to methadone, cyclazocine and naloxone; and indeed, the experiences and potential usefulness of a heroin challenge test might be a more useful section. Especially, if it were introduced in the volume as part of Section V. Such a chapter could fall in Section IX.

We would propose to participate in this volume by providing a chapter on our neurophysiological studies. I am not sure how such data, especially since it would be heavily weighted with EEG figures, would be interpreted by biochemists reading the volume, but I am optimistic that the next few years may bring forth some theories of the relation of EEG changes to the biochemical changes of the brain. When that occurs, our data may be usefully interpreted by chemists.

If this suggestion is not consistent with your overall picture of the volume, and you still would like a clinical evaluation of the antagonists, we will be able to provide an up-to-date summary in the early spring. As co-contributors, I would like to invite Dr. Arthur Zaks and Dr. Alfred M. Freedman.